Coherus Claims COVID Delays As It Axes Avastin Biosimilar Program

Ending Innovent’s Avastin Partnership ‘Unfortunate Business Decision’

 
• By Dean Rudge
  
severing ties and boycott concept
Coherus has severed another of its biosimilar programs • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products